Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway

Yasushi Iida(Jikei University School of Medicine), Aikou Okamoto(Jikei University School of Medicine)
Research Square
August 10, 2023
Cited by 0


Related Papers